Sanofi pivots toward boosters after Covid vaccine delays

Sanofi ends development of Covid Messenger-RNA vaccine.

(Bloomberg) --Sanofi will focus on supplying Covid-19 booster shots and fine-tuning its messenger RNA platform for the next pandemic after delays placed the drugmaker at least a year behind rivals in developing vaccines. 

That means halting the development of the company’s experimental messenger RNA shot, which would be redundant by the time it becomes available next year, according to Thomas Triomphe, executive vice president of Sanofi’s vaccines unit. 

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Latest news

See all jobs